CoreWeave Faces Class Action Lawsuit Over Misleading Revenue Claims
CoreWeave Inc's stock fell by 5.06% as it crossed below the 5-day SMA, reflecting investor concerns amid ongoing legal troubles.
The company is facing a class action lawsuit initiated by Hagens Berman, alleging that CoreWeave misled investors about its ability to scale AI infrastructure, which has resulted in significant investor losses. The lawsuit claims that the company overstated its revenue capacity and failed to disclose operational delays at its Denton, Texas data center, leading to a drastic loss of investor confidence and a market capitalization drop of approximately $14 billion.
This legal action underscores the challenges CoreWeave faces in restoring investor trust and highlights the potential financial implications of the lawsuit on the company's future operations and revenue generation.
Trade with 70% Backtested Accuracy
Analyst Views on CRWV
About CRWV
About the author

- Earnings Miss: CoreWeave reported a Q4 loss of $0.56 per share on revenue of $1.57 billion, falling short of expectations for a $0.49 loss and $1.53 billion in revenue, indicating significant pressure in a competitive landscape.
- Aggressive Capex Plans: The company projected capital expenditures of $30 billion to $35 billion for 2026, more than double the $14.9 billion spent in 2025, reflecting a strong intent to invest in infrastructure but raising concerns about sustainable profitability.
- Negative Market Reaction: Following warnings from investor Michael Burry that CoreWeave resembles past tech bubble plays, shares fell 4% in premarket trading and dropped over 18% on Friday, marking the worst session in over six months, highlighting investor anxiety.
- Divergent Analyst Views: Despite challenges, analysts remain optimistic about long-term growth, with JPMorgan lowering its target to $90 but still implying an 18.5% upside, indicating confidence in the company's future potential amidst current setbacks.
- Class Action Filed: On March 1, 2026, Kessler Topaz Meltzer & Check, LLP announced a securities fraud class action lawsuit against CoreWeave, Inc. (NASDAQ:CRWV) for investors who purchased shares between March 28 and December 15, 2025, indicating significant legal risks that could impact the company's stock performance.
- Allegations of Misrepresentation: The lawsuit alleges that CoreWeave made false or misleading statements during the class period, overstating its ability to meet customer demand while failing to disclose its reliance on a single third-party data center supplier, which created substantial operational and delivery risks that could undermine investor confidence.
- Investor Action Guidance: Investors must apply to be appointed as lead plaintiffs by March 13, 2026, to represent all investors in the litigation; failure to do so will result in them being absent class members, potentially affecting their rights to any future recovery.
- Law Firm Credentials: Kessler Topaz Meltzer & Check, LLP is a leading U.S. law firm specializing in securities fraud class actions, having recovered over $25 billion for clients, showcasing its strong capabilities and influence in securities litigation.
- Class Action Deadline: Rosen Law Firm reminds investors who purchased CoreWeave securities between March 28, 2025, and December 15, 2025, that they must apply to be lead plaintiff by March 13, 2026, to represent other investors in the class action lawsuit.
- Lawsuit Background: The lawsuit alleges that CoreWeave made false and misleading statements during the class period, overstating its ability to meet customer demand and underestimating the risks associated with reliance on a single third-party data center supplier, which could materially impact the company's revenue.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its expertise and success in this field.
- Investor Action Advice: Investors can visit the Rosen Law Firm website or call toll-free for more information, emphasizing the importance of selecting qualified legal counsel to ensure proper representation in the lawsuit and avoid inexperienced intermediaries.
- Figma Investment Update: Ark Innovation ETF purchased additional shares of Figma on February 23, making it the 38th largest holding at 0.66% of the total portfolio; despite concerns about slowing growth, Figma's 40% year-over-year sales increase in Q4 indicates strong market potential.
- CRISPR Holdings Overview: On February 20, Ark increased its stake in CRISPR Therapeutics, now the second-largest holding at 6.64% of the fund, with only $3.5 million in sales last year, yet the potential commercialization of gene-editing drugs could lead to explosive growth, representing a high-risk, high-reward investment.
- CoreWeave Investment Outlook: Ark also bought more shares of CoreWeave on February 20, making it the 18th largest holding at approximately 2% of the ETF; the company is benefiting from surging AI processing demand and is expected to see significant sales growth with large orders on the horizon.
- Market Reaction Analysis: Although the performance of Ark Innovation ETF has been mixed, Cathie Wood's continued investment in these high-risk stocks reflects her strong confidence in the innovation sector, which may significantly impact the fund's overall performance in the coming years.
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action against CoreWeave and its executives for securities fraud, alleging that the company concealed significant construction delays at its data centers, leading to substantial investor losses and highlighting major operational failures in meeting customer demand.
- Stock Volatility: On November 11, 2025, CoreWeave's stock plummeted by over 16%, dropping from $105.61 to $88.39, following a revenue and operating income guidance cut, indicating severe market skepticism regarding the company's operational capabilities.
- Merger Failure Impact: The failure of Core Scientific to secure enough shareholder votes for the merger with CoreWeave resulted in a more than 6% drop in stock price on October 30, 2025, from $139.93 to $131.06, underscoring the merger's critical importance for the company's future growth prospects.
- Legal Consequences: Investors have until March 13, 2026, to apply to lead the case, and if successful, this could exert pressure on CoreWeave's management to enhance transparency and compliance, aiming to restore market confidence.

- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against CoreWeave in the U.S. District Court for New Jersey on behalf of investors who purchased securities between March 28, 2025, and December 15, 2025, indicating significant legal exposure for the company.
- Allegations of Misrepresentation: The lawsuit alleges that CoreWeave's management issued false and misleading statements, failing to disclose the risks associated with reliance on a single third-party data center supplier, which could materially impact the company's revenue.
- Investor Rights Protection: Affected investors must apply by March 13, 2026, to be appointed as lead plaintiff in the lawsuit, with the law firm offering free consultations to safeguard investor rights and interests.
- Law Firm Credentials: Bragar Eagel & Squire is a nationally recognized law firm specializing in securities rights, representing both individual and institutional investors, and has extensive litigation experience in federal and state courts.






